4-heptyl methyl sulfide | 74585-45-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-heptyl methyl sulfide
• 英文别名: 4-methylsulfanyl-heptane；4-Methylsulfanylheptane
• CAS: 74585-45-8
• 化学式: C₈H₁₈S
• 分子量: 146.297
• InChiKey: ADZAEUFCTQARFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  溴甲烷 、 4-heptyl methyl sulfide 生成 dimethyl-(1-propyl-butyl)-sulfonium; bromide
  参考文献：
  名称：

  Franzen,V.; Mertz,C., Chemische Berichte, 1960, vol. 93, p. 2819 - 2824

  摘要：

  DOI：
• 作为产物：
  描述：

  5-十一酮 在 六甲基磷酰三胺 、 正丁基锂 、 对甲苯磺酸 作用下， 以 苯 为溶剂， 生成 4-heptyl methyl sulfide
  参考文献：
  名称：

  Metalation of 1,3-dithiolanes. Mercaptan synthesis and carbonyl transposition

  摘要：

  DOI：

  10.1021/ja00530a043

文献信息

• 10.1021/jacs.4c04855
  作者：Liu, Zhenzhong、Wu, Hongli、Zhang, Helong、Wang, Fang、Liu, Xiaohua、Dong, Shunxi、Hong, Xin、Feng, Xiaoming

  DOI：10.1021/jacs.4c04855

  日期：——

  molecules and synthesis of the chiral insecticide sulfoxaflor and the intermediates of related bioactive compounds. Based on experimental studies and theoretical calculations, a water-bonded high-spin iron nitrenoid species was identified as the key intermediate. The observed stereoselectivity was original from the steric repulsion between the amide unit of the ligand in the chiral cave and the bulky substituent

  过渡金属催化的对映选择性氮宾转移到硫化物已成为快速构建对映体富集的硫酰亚胺的最有力的策略之一。然而，与贵金属相比，实现对地球丰富的高活性过渡金属氮烯中间体的立体控制仍然是一个艰巨的挑战。在此，我们公开了使用亚氨基碘烷作为氮宾前体的手性铁(II)/ N , N'-二氧化物催化的二烷基硫醚和烷基芳基硫醚的对映选择性酰亚胺化。以中等至良好的收率和高对映选择性获得了一系列手性磺酰亚胺（56 个实例，收率高达 99%，98:2 er）。通过复杂分子的后期修饰以及手性杀虫剂氟啶虫胺和相关生物活性化合物中间体的合成，证明了该方法的实用性。基于实验研究和理论计算，水键合的高自旋铁氮化物被确定为关键中间体。观察到的立体选择性源于手性洞穴中配体的酰胺单元与硫化物的大取代基之间的空间排斥。此外，二恶唑酮被证明是在铁(III)/ N , N'-二氧化物络合物存在下合适的酰基氮烯前体，导致形成对映选择性反转的硫酰亚
• WILSON S. R.; GEORGIADIS G. M.; KHATRI H. N.; BARTMESS J. E., J. AMER. CHEM. SOC., 1980, 102, NO 10, 3577-3583
  作者：WILSON S. R.、 GEORGIADIS G. M.、 KHATRI H. N.、 BARTMESS J. E.

  DOI：——

  日期：——
• PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION
  申请人：NADLER Jerry L.

  公开号：US20080300189A1

  公开（公告）日：2008-12-04

  Pharmaceutical compositions and methods for using are provided for restoring β-cell mass and function in a mammal in need thereof. The pharmaceutical compositions have a biological response modifier and a β-cell growth factor in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.
• ENCAPSULATION SYSTEM
  申请人：Nadler Jerry L.

  公开号：US20090269313A1

  公开（公告）日：2009-10-29

  An encapsulation system for use in the treatment of diabetes (Types 1 or 2, and LADA) are provided. The system has (1) a delivery vehicle comprising a selectively permeable membrane that allows passage of glucose, insulin and other nutrients through the membrane, but prevents large molecules such as antibodies or inflammatory cells from passing through the membrane; (2) a population of islet cells or insulin producing cells encapsulated by said membrane; and (3) a biological response modifier that may be in contact with the membrane or encapsulated by the membrane. Generally, the biological response modifier is a compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula: wherein: X, Y and Z are independently selected from a member of the group consisting of C(R 3 ), N, N(R 3 ) and S; R 1 is selected from a member of the group consisting of hydrogen, methyl, C (5-9) alkyl, C (5-9) alkenyl, C (5-9) alkynyl, C (5-9) hydroxyalkyl, C (3-8) alkoxyl, C (5-9) alkoxyalkyl, the R 1 being optionally substituted; R 2 and R 3 are independently selected from a member of the group consisting of hydrogen, halo, oxo, C (1-20) alkyl, C (1-20) hydroxyalkyl, C (1-20) thioalkyl, C (1-20) alkylamino, C (1-20) alkylaminoalkyl, C (1-20) aminoalkyl, C (1-20) aminoalkoxyalkenyl, C (1-20) aminoalkoxyalkynyl, C (1-20) diaminoalkyl, C (1-20) triaminoalkyl, C (1-20) tetraaminoalkyl, C (5-15) aminotrialkoxyamino, C (1-20) alkylamido, C (1-20) alkylamidoalkyl, C (1-20) amidoalkyl, C (1-20) acetamidoalkyl, C (1-20) alkenyl, C (1-20) alkynyl, C (3-8) alkoxyl, C (1-11) alkoxyalkyl, and C (1-20) dialkoxyalkyl.
• COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE
  申请人：Nadler Mary Ann Latona

  公开号：US20110052625A1

  公开（公告）日：2011-03-03

  Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline analogs (LSF analogs) are immunomodulators that reduce interlukin 12 signaling and reduce the onset of T1DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF analog (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of an LSF analog and INGAP after pre-treatment with an LSF analog is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal.